PRELUDE THERAPEUTICS INC Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
PRELUDE THERAPEUTICS INC (PRLD) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 673.54 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-11
- PRELUDE THERAPEUTICS INC share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 89.77K shares, a 78.87% decline year-over-year.
- PRELUDE THERAPEUTICS INC share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 583.77K shares, a 35.24% decline year-over-year.
- PRELUDE THERAPEUTICS INC share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 968.89K shares, a 5.74% increase year-over-year.
- PRELUDE THERAPEUTICS INC share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 968.50K shares, a 304.43% increase year-over-year.
- PRELUDE THERAPEUTICS INC share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 3.26M shares, a 104.79% increase from fiscal 2024.
- PRELUDE THERAPEUTICS INC share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 1.59M shares, a 126.23% increase from fiscal 2023.
- PRELUDE THERAPEUTICS INC share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 704.48K shares, a 51.58% decline from fiscal 2022.
- PRELUDE THERAPEUTICS INC share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 1.46M shares, a 15.13% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 89.77K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | 673.54K shares 10-Q · filed 2026-08-11 | 1.64M shares derived: sum of 3 quarters · filed 2026-08-11 | 2.61M shares derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | 583.77K shares 10-Q · filed 2026-05-12 | 1.55M shares derived: sum of 2 quarters · filed 2026-05-12 | 2.52M shares derived: sum of 3 quarters · filed 2026-05-12 | 2.95M shares derived: sum of 4 quarters · filed 2026-05-12 |
| 2025-12-31 | 968.89K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | 1.94M shares derived: sum of 2 quarters · filed 2026-03-10 | 2.36M shares derived: sum of 3 quarters · filed 2026-03-10 | 3.26M shares 10-K · filed 2026-03-10 |
| 2025-09-30 | 968.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | 1.39M shares derived: sum of 2 quarters · filed 2025-11-12 | 2.29M shares 10-Q · filed 2025-11-12 | 3.21M shares derived: sum of 4 quarters · filed 2026-03-10 |
| 2025-06-30 | 424.95K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | 1.33M shares 10-Q · filed 2025-08-14 | 2.24M shares derived: sum of 3 quarters · filed 2026-03-10 | 2.48M shares derived: sum of 4 quarters · filed 2026-03-10 |
| 2025-03-31 | 901.47K shares 10-Q · filed 2025-05-06 | 1.82M shares derived: sum of 2 quarters · filed 2026-03-10 | 2.06M shares derived: sum of 3 quarters · filed 2026-03-10 | 2.26M shares derived: sum of 4 quarters · filed 2026-03-10 |
| 2024-12-31 | 916.33K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | 1.16M shares derived: sum of 2 quarters · filed 2026-03-10 | 1.36M shares derived: sum of 3 quarters · filed 2026-03-10 | 1.59M shares 10-K · filed 2026-03-10 |
| 2024-09-30 | 239.47K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | 446.58K shares derived: sum of 2 quarters · filed 2024-11-06 | 677.42K shares 10-Q · filed 2024-11-06 | 1.05M shares derived: sum of 4 quarters · filed 2025-03-10 |
| 2024-06-30 | 207.11K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | 437.95K shares 10-Q · filed 2024-08-12 | 811.49K shares derived: sum of 3 quarters · filed 2025-03-10 | 875.08K shares derived: sum of 4 quarters · filed 2025-03-10 |
| 2024-03-31 | 230.84K shares 10-Q · filed 2024-05-07 | 604.38K shares derived: sum of 2 quarters · filed 2025-03-10 | 667.96K shares derived: sum of 3 quarters · filed 2025-03-10 | 736.49K shares derived: sum of 4 quarters · filed 2025-03-10 |
| 2023-12-31 | 373.55K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | 437.13K shares derived: sum of 2 quarters · filed 2025-03-10 | 505.65K shares derived: sum of 3 quarters · filed 2025-03-10 | 704.48K shares 10-K · filed 2025-03-10 |
| 2023-09-30 | 63.58K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | 132.10K shares derived: sum of 2 quarters · filed 2023-11-01 | 330.94K shares 10-Q · filed 2023-11-01 | 748.64K shares derived: sum of 4 quarters · filed 2024-02-15 |
| 2023-06-30 | 68.52K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | 267.36K shares 10-Q · filed 2023-08-03 | 685.06K shares derived: sum of 3 quarters · filed 2024-02-15 | 876.91K shares derived: sum of 4 quarters · filed 2024-02-15 |
| 2023-03-31 | 198.83K shares 10-Q · filed 2023-05-08 | 616.54K shares derived: sum of 2 quarters · filed 2024-02-15 | 808.39K shares derived: sum of 3 quarters · filed 2024-02-15 | 1.46M shares derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-12-31 | 417.71K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | 609.56K shares derived: sum of 2 quarters · filed 2024-02-15 | 1.26M shares derived: sum of 3 quarters · filed 2024-02-15 | 1.46M shares 10-K · filed 2024-02-15 |
| 2022-09-30 | 191.85K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | 845.52K shares derived: sum of 2 quarters · filed 2022-11-14 | 1.04M shares 10-Q · filed 2022-11-14 | 1.94M shares derived: sum of 4 quarters · filed 2023-03-15 |
| 2022-06-30 | 653.67K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | 845.52K shares 10-Q · filed 2022-08-09 | 1.74M shares derived: sum of 3 quarters · filed 2023-03-15 | 2.07M shares derived: sum of 4 quarters · filed 2023-03-15 |
| 2022-03-31 | 191.85K shares 10-Q · filed 2022-05-10 | 1.09M shares derived: sum of 2 quarters · filed 2023-03-15 | 1.42M shares derived: sum of 3 quarters · filed 2023-03-15 | 1.44M shares derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-12-31 | 898.74K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | 1.23M shares derived: sum of 2 quarters · filed 2023-03-15 | 1.25M shares derived: sum of 3 quarters · filed 2023-03-15 | 1.26M shares 10-K · filed 2023-03-15 |
| 2021-09-30 | 330.16K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | 353.72K shares derived: sum of 2 quarters · filed 2021-11-12 | 365.15K shares 10-Q · filed 2021-11-12 | 365.15K shares derived: sum of 4 quarters · filed 2022-03-17 |
| 2021-06-30 | 23.57K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | 34.99K shares 10-Q · filed 2021-08-12 | 34.99K shares derived: sum of 3 quarters · filed 2022-03-17 | |
| 2021-03-31 | 11.42K shares 10-Q · filed 2021-05-11 | 11.42K shares derived: sum of 2 quarters · filed 2022-03-17 | ||
| 2020-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | 115.74K shares 10-K · filed 2022-03-17 | ||
| 2020-09-30 | 115.74K shares 10-Q · filed 2020-11-10 | |||
| 2019-12-31 | 3.24K shares 10-K · filed 2021-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |